This page is currently being updated and revised

Bedside to bench and back forward.

Here we listed a selection of original contribution of the company’s founder published in high-ranking international peer-reviewed journals related to the specific topics.

Medical translational research takes up problems related to our patients into the lab. Here, a multi-disciplinary team in basic science helps to make results useful for practical applications to enhance our understanding of disease, develop new diagnostics and translate our findings into new therapeutic options. Curiosity, precision, well-founded and sound scientific knowledge with a good feeling for relevant problems characterise academic research with clinical applicability. It is now well-known that circulating angiogenic cells play an indespensible role in vascular regeneration and organ preservation. Our work has been reproduced and cited manifold.

Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005

Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S, Zeiher AM. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapy. Eur Heart J 2006

Schmidt-Lucke, C, S Fichtlscherer, A Aicher, C Tschöpe, H-P Schultheiss, A M Zeiher, S Dimmeler. Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol. PLoS ONE 2010

C. Schmidt-Lucke, Stephan Fichtlscherer, Lothar Rössig, Ulrike Kämper, Stefanie Dimmeler. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis 2010

GP Fadini, Maruyama S, Ozaki T, Taguchi A, Meigs J, Dimmeler S, Zeiher A, de Kreutzenberg S, Avogaro A, Nickenig G, C Schmidt-Lucke , Werner N. Circulating progenitor cell count for cardiovascular risk stratification. A pooled analysis. PLoS ONE 2010

International approval with one idea.

Despite the knowledge that eating slowly significantly lowers meal energy intake and hunger ratings, individuals do not implement this behaviour. After dieting, usually weight regain is the consequense. Not in the case of a novel non-invasive medical device, where patients with increased cardiovascular risk profile had long-term weight reduction in a prospective trial. Currently, the results of the prospective, randomised, single-blinded, are eagerly awaited to confirm the initial results.

P. von Seck, F. M. Sander, L. Lanzendorf, S. von Seck, A. Schmidt-Lucke, M. Zielonka, C. Schmidt-Lucke. Persistent Weight Loss with a Non-invasive Novel Medical Device to Change eating behaviour In Obese Individuals With High-risk Cardiovascular Risk Profile, PLoS ONE 2017

Change guidelines.

The ACE-Study was widely acceclaimed and received great international interest. This investigator-initiated study broadened the indication of Enoxaparin. In this randomised, prospective multicentre-study Enoxaparin showed non-inferior to unfractionated heparin and phenprocoumon in TEE-guided cardioversion of persistent non-valvular atrial fibrillation.

Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel WG, Hanrath P, Mugge A, Klein HU, Schmidt-Lucke JA. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Thromb Res. 2007

Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004

Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion — the ACE study (Anticoagulation in Cardioversion using Enoxaparin), Card Electrophysiol Rev. 2003

Schadlich PK, Schmidt-Lucke C, et al. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation : a statutory health insurance perspective from Germany. Am J Cardiovasc Drugs. 2007

Tread new paths. Think unusual. Free of conventions.

Pattern of clinical disease caused by human parvovirus B19 (B19V) is generally a self-limiting subclinical disorder. However, in certain individuals B19V is a fatal disease. B19 V is the most common viral pathogen associated with inflammatory cardiomyopathy. Interestingly, B19V infection is restricted to cardiac endothelial cells, but not cardiomyocytes in this disease. B19V infection of endothelial cells results in apoptosis, the programmed cell death. Patients with B19V cardiomyopathy present with endothelial dysfunction and show elevated numbers of circulating apoptotic endothelial cells. How can B19V persist in the heart over long time periods? What are the mechanisms of damage in B19V-infected bone marrow-derived cells? These findings are being published shortly in a high-ranking journal.

C. Schmidt-Lucke, T. Zobel, F. Escher, C. Tschöpe, D. Lassner, U. Kühl, K. Gubbe, H. D. Volk, H. P. Schultheiss. Human Parvovirus B19 (B19V) Up-regulates CXCR4 Surface Expression of Circulating Angiogenic Cells: Implications for Cardiac Ischemia in B19V Cardiomyopathy. J Infect Dis. 2018

C. Schmidt-Lucke, F. Spillmann, T. Bock, S. van Linthout, M. Meloni, U. Kühl, D. Lassner, H.-P. Schultheiss, C. Tschöpe. Interferon-beta modulates endothelial damage in patients with cardiac persistence of parvovirus B19. JID. 2010

Pozzuto T, von Kietzell K, Bock T, Schmidt-Lucke C, Poller W, Zobel T, Lassner D, Zeichhardt H, Weger S, Fechner H. Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions.Virology. 2011

C. Schmidt-Lucke, F. Escher, S. Van Linthout, U. Kuhl, k. Miteva, J. Ringe, T. Zobel, H.P. Schultheiss, C. Tschöpe. Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy. Mediators Inflamm. 2015

C. Schmidt-Lucke, T Zobel, S. Schrepfer, U. Kuehl, D. Wang, K. Klingel P. M. Becher, H. Fechner, T. Pozzuto, S. van Linthout, D. Lassner, F. Spillmann, F. Escher, S. Holinski, H.D. Volk, T. Bock, H.-P. Schultheiss, C. Tschöpe. Impaired endothelial regeneration through human parvovirus B19-infected circulating angiogenic cells in cardiomyopathy. JID. 2015